| Authors: |
Watterson A; Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK; Open Targets, Cambridgeshire, UK., Picco G; Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK; Open Targets, Cambridgeshire, UK., Veninga V; Department of Immunology and Molecular Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands., Samarakoon Y; Cancer Research UK, Cambridge Institute, University of Cambridge, Cambridge, UK., Cattaneo CM; Department of Immunology and Molecular Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands., Vieira SF; Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK; Open Targets, Cambridgeshire, UK., Karakoc E; Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK; Open Targets, Cambridgeshire, UK., Bhosle S; Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK., Battaglia TW; Department of Immunology and Molecular Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Consonni S; Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK; Open Targets, Cambridgeshire, UK., Halim TYF; Cancer Research UK, Cambridge Institute, University of Cambridge, Cambridge, UK., Voest EE; Department of Immunology and Molecular Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands., Garnett MJ; Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK; Open Targets, Cambridgeshire, UK., Coelho MA; Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK; Open Targets, Cambridgeshire, UK. Electronic address: matthew.coelho@sanger.ac.uk. |
